



(TRANSLATION FROM THE GERMAN LANGUAGE – FOR YOUR CONVENIENCE ONLY)

Statement of the Executive Board regarding agenda items 7 and 8

Dear shareholders,

With respect to the agenda items 7 and 8 of our Annual General Shareholders' Meeting on 10 June 2008, the Executive Board of STADA Arzneimittel AG expressly draws your attention to the following:

The Executive Board has resolved to utilise the authorisations submitted for approval by the Annual General Shareholders' Meeting on 10 June 2008:

- to increase the share capital from the authorised share capital (agenda item 7)
- to issue bonds with warrants and/or convertible bonds (agenda item 8)

in each case with regard to the exclusion of subscription rights only subject to the following restrictions:

The utilisation by the Executive Board of the abovementioned authorisations (agenda items 7 and 8) by way of excluding subscription rights of the shareholders will be limited to an aggregate amount of 20% of the outstanding share capital at the time of the effective date of one of the abovementioned authorisations or – if this amount is lower – at the time of the first utilisation of one of the abovementioned authorisations. The capital increases by way of excluding subscription rights of the shareholders on the basis of the abovementioned

Executive Board: Hartmut Retzlaff (Chairman) / Dipl.-Kfm. Wolfgang Jeblonski / Dr. Alexander Oehmichen / Christof Schumann / Dr. Hans-Martin Schwarm
Chairman of the Supervisory Board: Dr. Eckhard Brüggemann



authorisations (agenda items 7 and 8) are limited to a maximum of EUR 30,538,404.00 corresponding to 11,745,540 registered shares with restricted transferability.

The Executive Board will make this statement at the Annual General Shareholders' Meeting on 10 June 2008. The Executive Board hereby requests you, to take this fact into consideration when exercising your voting rights.

Yours sincerely,

STADA Arzneimittel AG

The Executive Board

Executive Board: Hartmut Retzlaff (Chairman) / Dipl.-Kfm. Wolfgang Jeblonski / Dr. Alexander Oehmichen / Christof Schumann / Dr. Hans-Martin Schwarm
Chairman of the Supervisory Board: Dr. Eckhard Brüggemann